SLNO - CIK 0001484565
SOLENO THERAPEUTICS INC trades as SLNO and has a market capitalization of $2.76 B, making it the #1877 largest US-listed company by market value. In its fiscal 2016 annual report the company posted revenue of $1.45M, up 138.8% from the prior year and net income of $20.89M. This page tracks SOLENO THERAPEUTICS INC through 1,119 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| POS AM | - | 2026-05-21 |
| AW | - | 2026-05-21 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio | Soleno Therapeutics Inc.
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer | Soleno Therapeutics Inc.
Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR | Soleno Therapeutics Inc.
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, www.soleno.life .
Soleno Therapeutics to Participate in Upcoming Conferences | Soleno Therapeutics Inc.
The largest companies sharing SOLENO THERAPEUTICS INC's SEC industry classification (pharmaceutical preparations).
SOLENO THERAPEUTICS INC (SLNO) has a market capitalization of $2.76 B as of 2026-06-10, ranking #1877 among US-listed companies.
SOLENO THERAPEUTICS INC reported revenue of $1.45M for fiscal year 2016, an increase of 138.8% year over year.
Yes. SOLENO THERAPEUTICS INC reported net income of $20.89M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.